StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M) ($M)

Form 10-K / 10-Q Note (Revenue Recognition — Remaining Performance Obligations)

QuarterlyAnnual
Latest, Q2 2026
6,200
Period ended Jun 30, 2026
Change on a year earlier
+5.1%
5,900 in Q2 2025
History
30 quarters
Since Q4 2018
Sources
30
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDiagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20266,200+5.1%SEC Filing (0001628280-26-050134) ↗
Q1 2026Mar 31, 20266,200+8.8%SEC Filing (0001628280-26-028357) ↗
Q4 2025Dec 31, 20256,100+10.9%SEC Filing (0001628280-26-010185) ↗
Q3 2025Sep 30, 20256,000+13.2%SEC Filing (0001628280-25-047131) ↗
Q2 2025Jun 30, 20255,900+22.9%SEC Filing (0001628280-25-036720) ↗
Q1 2025Mar 31, 20255,700+26.7%SEC Filing (0001628280-25-021090) ↗
Q4 2024Dec 31, 20245,500+25.0%SEC Filing (0001628280-25-007110) ↗
Q3 2024Sep 30, 20245,300+26.2%SEC Filing (0001628280-24-044602) ↗
Q2 2024Jun 30, 20244,800+14.3%SEC Filing (0001628280-24-033740) ↗
Q1 2024Mar 31, 20244,500+9.8%SEC Filing (0001628280-24-020011) ↗
Q4 2023Dec 31, 20234,400+10.0%SEC Filing (0001628280-24-005348) ↗
Q3 2023Sep 30, 20234,200+7.7%SEC Filing (0001628280-23-035957) ↗
Q2 2023Jun 30, 20234,200+7.7%SEC Filing (0001628280-23-027203) ↗
Q1 2023Mar 31, 20234,100+7.9%SEC Filing (0001628280-23-015699) ↗
Q4 2022Dec 31, 20224,0000.0%SEC Filing (0001628280-23-004026) ↗
Q3 2022Sep 30, 20223,9000.0%SEC Filing (0001628280-22-027550) ↗

Cite this data

StockData. (2026). Abbott Laboratories Diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M) ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rpo

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.